The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | The state of clinical myeloma research in the UK
In this video, Graham Jackson, MBBS, FRCP, FRCPath, MD, Newcastle upon Tyne Hospitals NHS Trust, Newcastle, UK, briefly comments on the state of clinical myeloma research in the UK, which he describes as being in a “healthy place”. Prof. Jackson attributes this success to a collaborative effort among researchers and clinicians across the country and looks forward to future research directions. This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So my talk today was about the state of health of research in the UK and I think it’s a very healthy place. Not necessarily for commercial studies but our academic studies are really top-line and we are and have made a huge difference in terms of the outcomes that we’ve described from our trials.
I think the most important thing is it’s a very collaborative effort...
So my talk today was about the state of health of research in the UK and I think it’s a very healthy place. Not necessarily for commercial studies but our academic studies are really top-line and we are and have made a huge difference in terms of the outcomes that we’ve described from our trials.
I think the most important thing is it’s a very collaborative effort. We’ve got a great team. So included in that would be the trials team at Leeds, the genetics team at the Marsden, the immunology team at Birmingham. But I think most of all, we have fantastic researchers who around the country contribute lots of patients to the studies. So I think we are in a healthy place and now we have RADAR and we’re looking to a future elderly study. I think those studies will continue to be very important.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Johnson & Johnson, Amgen, Sanofi, Bristol Myers Squibb, Takeda, Pfizer, Menarini: Honoraria for advisory boards/speaking; Onyx, Bristol Myers Squibb, Takeda: Research Funding.
